S100A9 and hypertriglyceridemia: Accordingly, DT-treated RIP-DTR; S100a9+/+ mice acquired severe hypoinsulinemia, hyperketonemia, hyperglycemia, hypertriglyceridemia and reduced body weight compared to their DT-untreated RIP-DTR; S100a9+/+ healthy controls (Supplementary Fig. 1A–E).